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Abstract
Background. Precision medicine trials targeting  the epidermal growth factor receptor (EGFR) in glioblastoma 
patients require selection for EGFR-amplified tumors. However, there is currently no gold standard in determining 
the amplification status of EGFR or variant III (EGFRvIII) expression. Here, we aimed to determine which technique 
and which cutoffs are suitable to determine EGFR amplification status. 
Methods. We compared fluorescence in-situ hybridization (FISH) and real-time quantitative (RT-q)PCR data from 
patients screened for trial inclusion into the Intellance 2 clinical trial, with data from a panel-based next generation 
sequencing (NGS) platform (both DNA and RNA). 
Results. By using data from >1000 samples, we show that at least 50% of EGFR amplified nuclei should be present 
to define EGFR gene amplification by FISH. Gene amplification (as determined by FISH) correlates with EGFR 
expression levels (as determined by RT-qPCR) with receiver operating characteristics analysis showing an area 
under the curve of up to 0.902. EGFR expression as assessed by RT-qPCR therefore may function as a surrogate 
marker for EGFR amplification. Our NGS data show that EGFR copy numbers can strongly vary between tumors, 
with levels ranging from 2 to more than 100 copies per cell. Levels exceeding 5 gene copies can be used to define 
EGFR-amplification by NGS; below this level, FISH detects very few (if any) EGFR amplified nuclei and none of the 
samples express EGFRvIII. 
Conclusion. Our data from central laboratories and diagnostic sequencing facilities, using material from patients 
eligible for clinical trial inclusion, help define the optimal cutoff for various techniques to determine EGFR amplifi-
cation for diagnostic purposes.
Key Points
1. We show which cutoffs define EGFR amplification for diagnostic purposes.
2. Diagnostic EGFR amplification cutoffs are defined for FISH, RT-qPCR, and NGS.
3. EGFR gene expression can serve as a surrogate marker for EGFR amplification.
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In glioblastomas, the most common and aggressive type of 
primary brain tumor, the gene encoding epidermal growth 
factor receptor (EGFR) is mutated in approximately half of 
all tumors1,2 (Lassman et al, submitted). Initially, the EGFR 
locus is amplified to high copy number levels, sometimes 
exceeding 100 copies per tumor cell.3 Additional mutations 
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may evolve after gene amplification and these can in-
clude intragenic deletions, point mutations, and/or gene 
fusions.1 As secondary mutations mainly arise after gene 
amplification, they are almost always subclonal and it 
is not uncommon that several of these coexist within the 
same tumor. Secondary mutations in EGFR therefore add 
to the intratumoral heterogeneity of glioblastomas.4 EGFR 
amplicons are present in cells as double minutes: extra-
chromosomal and circular DNA fragments. These double 
minutes also contribute to tumor heterogeneity, as they are 
unevenly distributed across the 2 daughter cells following 
cell division.3
Although glioblastomas depend on EGFR for growth, 
clinical efficacy of EGFR tyrosine kinase inhibitors has thus 
far been disappointing.5–7 For example, in newly diagnosed 
glioma patients, gefitinib has no added clinical benefit 
when given after radiotherapy.8,9 Similarly, in recurrent 
glioma patients, erlotinib as single agent did not improve 
6 months progression-free survival.10,11 However, novel 
therapies that use EGFR either as a target or as a marker 
enriched in tumors, such as vaccines, chimeric antigen re-
ceptor T cells, or antibody drug conjugates, are under de-
velopment or are already in clinical trials for glioblastoma 
patients.12–16 Either way, clinical trials targeting EGFR re-
quire a consensus for the optimal method and cutoff to de-
termine EGFR amplification status.
The randomized phase II AbbVie M14-483/EORTC 1410-
BTG “Intellance 2” trial examined whether depatux-M 
improves survival in EGFR-amplified recurrent glioblas-
toma patients. Trial results show a trend toward improved 
survival when depatux-M was given in combination with 
temozolomide (TMZ) compared with an alkylator only–
based control arm. Longer-term follow-up confirmed 
improved survival (van den Bent et al, in preparation). 
For this trial, EGFR amplification was determined in a cen-
tral laboratory using fluorescence in-situ hybridization 
(FISH), and patients harboring EGFR-amplified tumors 
were selected from >1000 screened samples. Additional 
molecular studies on these samples was performed 
which included real-time quantitative (RT-q)PCR to de-
termine EGFR and variant III (EGFRvIII) expression and 
panel-based sequencing, but only of patients included in 
the trial (both DNA and RNA). The molecular data derived 
from central laboratory testing and diagnostic-grade 
sequencing facilities, using a clinically relevant patient 
population (ie, those eligible for clinical trial inclusion), 
help define the optimal cutoff for various techniques to 
determine EGFR amplification for diagnostic purposes. 
Our data can help the selection of patients into precision 
medicine trials.
Materials and Methods
Patients
Recurrent glioblastoma patients were considered eligible 
for the Intellance 2 trial (clinical trial identifier NCT02343406) 
if they had been diagnosed with a histologically confirmed, 
EGFR-amplified glioblastoma at first occurrence. For the 
screening assay, in the majority of cases (~86%), material 
from first surgery was used. This is possible since EGFR 
amplification is a temporally stable genetic event in the 
large majority of patients.17–19 A total of 1094 samples were 
screened from which 260 patients were randomized in the 
Intellance 2 trial to receive either (i) TMZ or, if progressing 
within 16 weeks of the start of the last maintenance TMZ 
cycle, CCNU (n = 26 and n = 60, respectively; total n = 
86); (ii) depatux-M alone (n = 86); or (iii) TMZ in combina-
tion with depatux-M (n = 88). A Consolidated Standards of 
Reporting Trials (CONSORT) diagram is shown in Figure 1. 
Eligibility criteria for molecular analysis were histologically 
confirmed de novo glioblastoma (primary) with unequiv-
ocal first progression after RT concurrent/adjuvant chemo-
therapy at least 3 months post radiotherapy, age ≥18 years, 
and Karnofsky performance status 60–100. All centers had 
to obtain approval of the study design from their local eth-
ical boards before study activation according to national 
and institutional regulations. All patients gave written in-
formed consent for trial participation and molecular testing.
Fluorescence In-Situ Hybridization 
FISH was performed by one of 3 laboratories (Histogenex, 
Antwerp, Belgium, n = 801; Mosaic, Lake Forest, California, 
n = 100; and Peter MacCallum Cancer Institute, Melbourne, 
Australia, n = 233) on glioblastomas using the Vysis EGFR 
CDx Assay (Abbott Molecular; not on market) as described 
(Lassman et al, submitted). Reproducibility between labs 
for FISH and RT-qPCR was determined using a proficiency 
tissue panel that was run on all sites upon startup. The 
proficiency of laboratory personnel to perform the Abbott 
RealTime EGFR assay was evaluated during RealTime 
EGFR assay training. The training/proficiency runs consist 
of a panel (glioblastoma formalin-fixed paraffin embedded 
[FFPE] tissue sections), EGFR positive and negative 
controls processed through all steps of the EGFR assay 
procedure (RNA isolation, amplification/detection reac-
tion setup, and operation of the m2000 Real Time System). 
The trainees were evaluated based on performance of 
Importance of the Study
Precision medicine trials targeting EGFR in glioblastoma 
patients require selection for EGFR-amplified tumors. 
However, there is currently no standard to determine the 
amplification status of EGFR or EGFRvIII expression. 
In this study, we used molecular data derived from cen-
tral laboratory testing and diagnostic-grade sequencing 
facilities, using a clinically relevant patient population 
(ie, those eligible for clinical trial inclusion) to help de-
termine which technique and which cutoffs are suitable 
to determine EGFR amplification status for diagnostic 
purposes. Our results are of high relevance for the se-
lection of patients into precision medicine trials.
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assay procedure as well as results of each proficiency run. 
One hundred percent concordance with expected results 
was one of the proficiency criteria. Data from all sites was 
evaluated by Abbott Molecular, and results were within ex-
pected range. For FISH, 2 DNA probes labeled with spec-
trally distinct fluorophores hybridizing to the 7p11.2-7p12 
region or the chromosome enumeration probe (CEP) 
7 hybridizing to the chromosome 7 centromere were 
used. Slides and probe mix were denatured at 73°C for 5 
minutes and then hybridized at 37°C for 14–24 hours on a 
ThermoBrite system (Abbott Molecular). Sample pretreat-
ment and post-hybridization washes were performed using 
the Vysis Universal FFPE Tissue Pretreatment and Wash 
Kit (Abbott Molecular; not commercially available). Slides 
were reviewed using fluorescence microscopy, and FISH 
signal counts (copy number) for individual probes were 
recorded for a total of 50 nuclei. A tumor was considered 
EGFR amplified when there was focal EGFR gene amplifi-
cation defined as an EGFR/CEP 7 ratio greater than or equal 
to 2 in ≥15% recorded cells. Tumors with polysomy for 
chromosome 7 (excess copies of the entire chromosome) 
but without focal amplification of the EGFR gene were 
considered to be EGFR nonamplified.
Real-Time Quantitative PCR 
RT-qPCR was performed as described (Lassman et al, 
submitted). Briefly, one ≥5 µM section containing a min-
imum of 50 mm2 total tissue area from a FFPE tumor 
block was processed for RNA extraction using the Qiagen 
RNeasy FFPE Extraction Kit (Qiagen Sciences) according 
to the manufacturer’s instructions. FFPE sections were 
deparaffinized, and proteinase K was added. The nucleic 
acids were de-crosslinked from formalin and DNase treated 
to remove DNA content. Purified RNA was combined in a 
96-well plate with mastermix containing primers and probes 
for amplification and detection of total EGFR and β-actin on 
the Abbott m2000 RealTime System (Abbott Molecular). 
β-actin served as an endogenous control and to provide 
relative quantitative values for total EGFR expression in 
the samples. The difference (ΔCt) between β-actin cycle 
threshold (Ct) and total EGFR Ct was calculated and reported.
  
Assessed for eligibility (n=1094)
Excluded  (n = 59)
• FISH uninformative (n = 39)
• RT-qPCR Actin uninformative (n = 2)
• RT-qPCR EGFR uninformative (n = 27)
Analysed for NGS (n = 226)
No Informed consent (n = 21)
NGS uninformative (n = 13)
EGFR amplified (n =  565)
• Intellance 2 included (n = 260)
• Intellance 2 not included (n = 305)
Not EGFR amplified (n = 470)
Analyzed for FISH and 
RT-qPCR (n = 1035)
Fig. 1 CONSORT diagram of the study population assessed for biomarkers.
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DNA/RNA Isolation and Sequencing
Materials, either tissue sections or tissue blocks, were cen-
trally collected at the Erasmus Medical Center in Rotterdam. 
Material of 226 patients included in the Intellance 2 trial was 
collected. Evaluation of the area with highest tumor con-
tent was done by the pathologist (J.M.K.) on a hematox-
ylin and eosin stained section. Ten to twenty 5-μm sections 
were then sent to Almac Diagnostics (Craigavon, UK) for 
macrodissection and subsequent DNA and RNA extraction 
using the Allprep DNA/RNA FFPE kit (Qiagen). Sequencing 
was done using the Trusight Tumor 170 panel (Illumina), 
which uses a combination of DNA and RNA sequencing 
to interrogate single nucleotide variations (SNVs) in ~150 
genes, amplification of 59 genes, and fusion and splice 
variant expression in 55 genes.20 Sufficient quality was 
obtained in 216 samples for DNA sequencing and 215 for 
RNA sequencing. SNV, copy number, fusion gene, and 
splice variant expression calling was done on the Illumina 
Basespace sequence hub using the TruSight Tumor 170 App.
For each sample of the 1094 patients, one FISH assess-
ment and one RT-qPCR value for EGFR, actin, and EGFRvIII 
was available. For 226 of these, the additional NGS data are 
available with one EGFR amplification level value (derived 
from a combination of probes on the EGFR locus, deter-
mined by the standard TruSight170 pipelines on the Illumina 
Basespace sequencing hub). EGFR amplification status by 
FISH was initially dichotomized as per trial inclusion (ie, 
using a cutoff of 15% amplified nuclei per tumor unless oth-
erwise stated). EGFR amplification status as determined 
by RT-qPCR was dichotomized based on the bimodal dis-
tribution of the frequency histogram using ΔCt values 
stated in the analysis. Mean and cutoff values of bimodal 
distributions were determined based on a finite mixture 
model using the Expectation-Maximization algorithm and 
calculated based on the “cutoff” R package.21 This package 
was also identified the cutoff point for FISH to determine 
EGFR amplification. The ΔCt value with highest AUC (−3.56) 
and with a type I error rate of 0.05 (−2.48) was used to show 
concordance between FISH and RT-qPCR. Comparison be-
tween frequencies was done using the chi-square test. 
Kappa scores were calculated using the interrater reliability 
and agreement “irr” package in R. Where applicable, values 
listed with 95% confidence intervals or ±SD.
Results
For inclusion in the Intellance 2 trial, 1094 recurrent glio-
blastoma patients were screened for EGFR amplification 
by FISH in a central laboratory. Of these, 1072 samples 
yielded informative data to determine EGFR amplification 
(a CONSORT diagram is shown in Figure 1). Fifty nuclei 
were counted per sample from which the percentage of 
EGFR-amplified cells was calculated. For each cell, EGFR 
amplification was defined when the ratio of EGFR/centro-
mere Chr 7 was >2. This would amount to a copy number 
of EGFR >6 per cell as most glioblastomas have gain of 
chromosome 7. Interestingly, and despite the fact that 
glioblastomas also harbor non-neoplastic stromal cells, 
the majority of samples either contain almost no EGFR 
amplified cells (<15% amplified nuclei) or consist entirely 
of EGFR amplified cells (>90% amplified nuclei; Figure 2). 
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Fig. 2 Frequency histogram of the percentage of EGFR-amplified nuclei per tumor sample by FISH (A). Note that most samples either contain 
almost no EGFR-amplified nuclei or almost entirely consist of EGFR-amplified nuclei. The histogram of EGFR RT-qPCR data (B) also shows a bi-
modal distribution suggesting that RT-qPCR data can also be used to determine EGFR amplification status. Models of the 2 distributions (dashed 
lines) are plotted on top of the frequency histogram. The intersect of these 2 curves at −3.56 gives highest concordance between FISH and 
RT-qPCR data. The cutoff value for type I errors in calling EGFR amplification was calculated at −2.48.
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Relatively few samples (n = 122, 11.6%) had intermediate 
numbers of EGFR-amplified nuclei. The FISH results there-
fore indicate that glioblastomas generally are not com-
posed of mixtures of EGFR-amplified and non-amplified 
cells.
RT-qPCR was successfully performed on 1035 tumors. 
The histogram of ΔCt values, plotted in Figure 2B, shows 
a bimodal distribution with two peaks at −6.1 ± 1.9 and 
−1.4 ± 1.4 ΔCt. Ranked ΔCt values, plotted in Figure 3A, 
show a wide range of EGFR expression between different 
tumors. EGFR expression was correlated to amplifica-
tion: the samples with high expression of EGFR almost al-
ways contained a high number of EGFR-amplified cells by 
FISH and, conversely, samples with low EGFR expression 
contained very few (if any) EGFR-amplified cells (Figure 
3B). A receiver operating characteristic (ROC) plot shows 
the strength of gene expression in determining gene 
amplification (Figure 3C). When EGFR amplification was 
defined as a tumor having greater than −3.56 ΔCt EGFR 
versus actin expression value (ie, the intersect of 2 curves 
modeling the bimodal distribution), the area under the 
curve was 0.902 (95% CI: 0.881–0.922), with an optimum 
(ie, the point with the best sum of sensitivity and speci-
ficity) at sensitivity of 85.6% and specificity of 91.2% (95% 
CI: 88.1%–93.3%). At a sensitivity of 90% the specificity 
was 75.9% (95% CI: 60.6–88.8%). When EGFR amplification 
was defined as the optimal for type I errors (ie, 0.05), the 
ΔCt EGFR versus actin expression value cutoff increased 
to −2.48. Also at this cutoff, the area under the curve re-
mains high, 0.883 (95% CI: 0.862–0.904), with a sensitivity 
of 90.1% and specificity of 83.4%. The RT-qPCR data there-
fore demonstrate that EGFR expression can function as a 
surrogate marker to define EGFR amplification. Of note, in 
these analyses, the optimal threshold to determine EGFR 
amplification by FISH was a percentage of EGFR amplified 
cells exceeding 77%; higher than the 15% used for clinical 
trial inclusion.
The concordance between dichotomized FISH and 
RT-qPCR data was high: 89% using the RT-qPCR cutoff of 
−3.56 ΔCt values and 86% using the cutoff optimized for 
type I errors of −2.48 ΔCt values (both using a FISH cutoff 
of 77%% amplified cells; Table 1). Of course, any increase 
in stringency to define EGFR amplification (by increasing 
the percentage of FISH positive cells) would reduce the 
number of EGFR-amplified tumors. Using the criteria for 
clinical trial inclusion (ie, >15% amplified cells), 565 of the 
1035 samples tested (54.6%) were defined as being EGFR 
amplified. When increasing the stringency to define EGFR 
amplification to >77% amplified cells by FISH, this number 
would decrease to 460 (44.4%).
EGFRvIII expression was also determined by RT-qPCR 
and yielded informative data in 1049 samples. Almost 
all the 263 samples expressing EGFRvIII were also EGFR 
amplified as defined by FISH (257/263, 97.7%, P < 0.001; 
Supplementary Figure 1A), and EGFRvIII expressing 
tumors were present mainly in samples with high levels 
of EGFR expression (Figure 4, Supplementary Figure 1B), 
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Fig. 3 RT-qPCR can function as a surrogate to determine EGFR amplification status. (A) Ranked ΔCt values from RT-qPCR data show a wide 
range of EGFR expression between samples. Samples with high EGFR expression often had EGFR amplification. (B) RT-qPCR plotted against the 
percentage of EGFR-amplified cells per sample highlights the observation that higher percentages of EGFR-amplified cells also express EGFR 
at higher levels. (C) ROC curves show that EGFR expression can predict EGFR gene amplification by FISH. ROC curves were plotted for 4 dif-
ferent cutoffs (% of EGFR-amplified cells) to determine EGFR amplification by FISH.
  
Table 1 Concordance between FISH and RT-qPCR
FISH Status (77%)
Negative Positive
RT-qPCR status  
ΔCt −3.56
Negative 506 49
Positive 69 411
 FISH Status (77%)
Negative Positive
RT-qPCR status  
ΔCt −2.48
Negative 539 107
Positive 36 353
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confirming that EGFRvIII is expressed almost exclusively in 
samples with EGFR amplification.
EGFR Amplification by NGS
A total of 260 of the 1094 centrally screened patients were 
included in the Intellance 2 randomized phase II clinical 
trial. Patients were selected based on the presence of EGFR 
amplification by FISH only, with amplification defined as 
>15% of nuclei containing an EGFR/centromere Chr 7 ratio 
>2. Targeted NGS using the Illumina Trusight 170 plat-
form was successfully performed (DNA) on 226 of these 
260 samples. Ranked copy number estimates from the 
sequencing data are plotted in Figure 5A and confirms that 
most samples indeed contain high copy gene amplifica-
tion. However, of the 226 samples sequenced, 30 samples 
(13.9%) were estimated to have fewer than 4 EGFR copy 
numbers. Most of these 30 low copy number samples 
also contained few EGFR-amplified cells as determined by 
FISH, and had low EGFR gene expression levels (Figure 
5B). The observation that samples with a low percentage 
of amplified nuclei often show no copy number alterations 
by NGS suggests that FISH should use a more stringent 
cutoff to molecularly determine EGFR amplification than 
the threshold used for this trial. Indeed, when EGFR am-
plification was redefined as having >50% amplified nuclei, 
the total number of EGFR amplified samples drops margin-
ally (n = 199/226), but the proportion of samples containing 
fewer than 4 EGFR copy numbers by NGS was reduced 29 
to 7. It should be noted, however, that cutoffs used to mo-
lecularly define EGFR amplification may not reflect clinical 
efficacy of targeted agents; precision medicine trials may 
use a different cutoff.
It is possible that these samples are actually EGFR 
amplified but had a low tumor cell content. However, 
all sections were marked for areas of high tumor con-
tent (>70% tumor cells) by a dedicated neuropathologist. 
Moreover, the ranked copy number variation data from 
NGS show a “shoulder” in EGFR copy number variation 
between <5 and >10 gene copies (Figure 5A). This shoulder 
can be explained by the fact that EGFR is present as double 
minutes, which facilitates rapid high copy number gains,3 
and thus argues against incorrect estimation of tumor per-
centage (when a smoother line may be expected). Finally, 
none of the 29 samples express EGFRvIII when EGFR copy 
numbers are low (<4), whereas the percentage is mark-
edly higher, 103 of 187 (55.1%), in samples with >4 copy 
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Fig. 4 EGFRvIII expression is found in samples with high levels of EGFR expression. As can be seen, samples that express EGFRvIII (y-axis) 
are found in samples that have high levels of EGFR expression (x-axis). Dark-gray dots indicate those that have been classified as EGFRvIII pos-
itive tumors (ie, Ct values of EGFRvIII <30).
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numbers (P < 0.0001; Supplementary Figure 1C). EGFR am-
plification precedes the rearrangement leading to EGFRvIII 
expression, and generally half of EGFR-amplified tumors 
express EGFRvIII.22 Therefore, the absence of EGFRvIII-
expressing cells in samples with <5 copy numbers (and 
<50% FISH positive cells) also suggests that the majority 
of these samples are incorrectly classified, with the used 
FISH cutoff, as EGFR amplified. Our data therefore strongly 
suggest that the cutoff to determine EGFR gene amplifica-
tion by FISH should be increased to a sample having >50% 
EGFR-amplified cells.
Basic patient demographics (age, sex, etc) were only col-
lected for samples that were included in the Intellance 2 
trial. Within this group, demographics between RT-qPCR-
high and RT-qPCR-low cohorts were similar for patients for 
which NGS was attempted (Supplementary Table 1).
The Trusight 170 platform also includes targeted RNA 
sequencing of ~60 genes (including EGFR) and was suc-
cessfully performed on 215 samples. Read depth of EGFR 
in this cohort was high; the median number of reads 
(combined reference and splice supporting reads) was 
37 000 (interquartile range, 23 000–60 000). Comparison in 
EGFR expression between RT-qPCR and RNA-seq shows 
a high concordance between the 2 techniques, with most 
samples that have low expression on both platforms also 
containing relatively few EGFR amplified nuclei by FISH 
(Figure 6A). EGFRvIII expression was detected in 107 and 
93 samples by RT-qPCR and RNA-seq respectively, with 91 
samples identified by both platforms, unweighted kappa 
score 0.829. The observation that RT-qPCR identifies more 
EGFRvIII-expressing samples may suggest this technique 
has a higher sensitivity to detect these aberrant transcripts, 
even despite the high read depth (Figure 6B).
Discussion
In the era of targeted treatments for cancer patients, 
identifying the target with an appropriate biomarker assay 
has become an essential part of both clinical studies and 
standard of care once shown effective. The biomarker 
assay used should be well validated: robust, reproduc-
ible, feasible, and predictive for outcome. The present 
study reviews 3 different assays to identify EGFR-amplified 
tumors, comparing 2 assays in the screened population 
and another technique for the randomized patients. In ad-
dition, the presence or absence of the EGFRvIII mutation is 
studied. EGFRvIII is a genomic rearrangement that occurs 
after EGFR amplification.22–24
FISH for EGFR amplification is usually seen as a gold 
standard for the diagnostics of EGFR amplification, but what 
cutoffs (the % of positive nuclei, and the optimal ratio of 
EGFR vs centromere 7) should be used is unclear. For this 
trial, the bar to call EGFR amplification was set low, in view 
of the observation of a response in a patient with a relatively 
low level of EGFR amplification.13,14,25,26 An advantage of 
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such a low bar in a targeted treatment trial is that it allows 
the assessment of efficacy of the investigational compound 
around the borders of the assay. By using data from >1000 
samples, we provide evidence that the cutoff to determine 
EGFR gene amplification by FISH should be increased, 
preferably to >50% of EGFR-amplified nuclei. Although the 
number of samples in the current study was large, valida-
tion of this observation in an independent cohort would 
strengthen our conclusions. Such cohorts are, however, at 
present unavailable.
Although this FISH cutoff may better determine EGFR 
amplification for diagnostic purposes, response predic-
tion in precision medicine trials (ie, the predictive power of 
EGFR amplification) may use different cutoff points. For ex-
ample, when EGFR-amplified cells exert a dominant effect 
on the non-amplified neoplastic cells (whereby the non-
amplified neoplastic cells depend on the EGFR-amplified 
cells), targeting the minority of EGFR-amplified cells may 
already provide clinical benefit. The observation of patients 
with relatively low levels of EGFR amplification respond to 
the combination of depatux-M + TMZ supports this notion.
Our data also demonstrate that EGFR expression can 
serve as a surrogate marker to determine EGFR gene am-
plification. However, where EGFR-FISH has a bimodal dis-
tribution, EGFR expression is much more a continuum. 
This continuum makes it more difficult to define the op-
timal cutoff for EGFR amplification. Of note, the bimodal 
distribution observed by FISH demonstrates that most 
tumors either have no amplified cells or consist entirely of 
amplified cells. This indicates that the frequency of mosaic 
amplification of various oncogenes as previously reported 
is therefore likely relatively low.27
In summary, the data described in the current study, 
obtained from central laboratories and diagnostic 
sequencing facilities and using material from patients el-
igible for clinical trial inclusion, help define the optimal 
cutoff for various techniques to determine EGFR ampli-
fication for selection into precision medicine trials. In the 
end, the most optimal cutoff should be established based 
on evidence of clinical activity in the positive versus the 
negative biomarker population. That analysis is currently 
ongoing. Regardless, although our study shows that these 
tests correlate, there is a clear gray zone in which samples 
test positive in one assay but not in another assay.
Supplementary Material
Supplementary data are available at Neuro-Oncology 
online.
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Fig. 6 RT-qPCR and NGS show high correlation in determining levels of EGFR and presence of EGFRvIII. (A) EGFR expression by RT-qPCR is 
highly correlated with expression derived from NGS data. (B) Samples in which EGFRvIII expression is identified by RT-qPCR (ie, ΔCt < 30) often 
also show detectable levels of EGFRvIII by panel-based RNA-seq.
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